3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Gastrointestinal Stromal Tumors
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Melanoma
2
Leukemia
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia, Biphenotypic, Acute
1
Hypereosinophilic Syndrome
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Digestive System Neoplasms
1
Desmoid Tumors
1
Dermatofibrosarcoma
1
Congenital Bone Marrow Failure Syndromes
1
Chordoma
1
Carcinoma, Adenoid Cystic
1
Blast Crisis
1
Interventions
Nivolumab
5
Cyclophosphamide
5
pembrolizumab
4
Ipilimumab
4
fludarabine phosphate
3
fludarabine
3
Specimen Handling
3
Radiosurgery
2
Magnetic Resonance Spectroscopy
2
Interleukin-2
2
Blood Specimen Collection
2
trametinib
1
tebentafusp
1
ruxolitinib
1
omipalisib
1
olaparib
1
lifileucel
1
binimetinib
1
belinostat
1
avelumab
1
Vorinostat
1
Valproic Acid
1
Tape Recording
1
Sunitinib
1
Spinal Puncture
1
Practice Guidelines as Topic
1
Pemetrexed
1
Methods
1
LY2940680
1
Iodized Oil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Imatinib Mesylate
×
90 days
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled